Project Grant R43AI136195

This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of polymer-phage nanoparticle conjugates to treat antibiotic-resistant wound biofilm infections. The $593,860 award to the University of Massachusetts aims to create new phage-polymer nanoparticles that can more effectively penetrate and eradicate bacterial biofilms compared to free phage therapies. The...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $184,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Florida International University (FIU) to optimize a novel antimicrobial peptide, A4-X7, for pulmonary delivery to combat antimicrobial-resistant respiratory infections. The funded research aims to prepare, characterize, and evaluate the antimicrobial and antibiofilm activities of the A4-X7 formulation for aerosolized...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is providing $208,125 to the University of Connecticut Health Center to develop an intralesional drug delivery strategy for treating infected wounds. The key products and services to be delivered include: Characterization of in situ formed microneedle-like drug depots and...

The University of Melbourne will receive $599,253 under a three-year Project Grant award from the Department of the Army Medical Command to develop antimicrobial peptide-selenium nanoparticle dressings. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve warfighter health and transform civilian healthcare. Specifically, the University will conduct research to enhance burn wound healing and prevent...

This $361,237 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a new class of species-specific antimicrobial peptides called PNA-STAMPS to target Streptococcus pneumoniae (Spn), a major human pathogen. The project builds on preliminary data showing that fusing a broad-spectrum antimicrobial peptide (AMP) to an Spn-specific secreted peptide can selectively eliminate...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

This $625,909 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research and development of a hydrogel platform technology for delivering topical bacteriophage therapy to treat antibiotic-resistant wound infections. The award aims to develop innovative methods for sustained local delivery of bacteriophages - viruses that kill...

This $367,577 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Adepthera LLC aims to develop a regenerative peptide therapy to accelerate pressure ulcer healing. Specifically, the award will fund research to identify an optimal formulation of a self-assembling adrenomedullin (ADM) analog gel that can improve local blood circulation and wound healing in aging and diabetic mouse models. The proposed therapy would be administered weekly or biweekly via...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...

Acatechol, Inc. was awarded a $274,982 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to develop an innovative anti-infective coating for Foley catheters. The project aims to create a hybrid coating that combines biofilm-repellent and antimicrobial properties to provide prolonged resistance against pathogen colonization and catheter-associated urinary tract infections (CAUTIs). This work is being conducted under the NSF Technology, Innovation, and...